Business, energy, technology, markets and global industry news from Business News Today

University of California San Francisco

PharmaDeviceNews University of California San Francisco
Roche is seeking to extend Enspryng into MOGAD after Phase 3 data showed a substantial reduction in neurological relapse risk. Representative image.
Pharma & Biotech

Jocasta Neuroscience partners with Diamond Therapeutics on three non-hallucinogenic drug candidates

Jocasta Neuroscience and Diamond Therapeutics will evaluate three psychedelic-inspired 5-HT2A receptor compounds for cognitive impairment and neurodegeneration. The agreement gives Jocasta an option to license successful candidates, but the molecules have not yet demonstrated clinical efficacy or an absence of hallucinogenic effects in humans.

Read More
A representative image illustrating Regeneron Pharmaceuticals’ Pasatru approval as the FDA clears the new fibrodysplasia ossificans progressiva treatment after Phase 3 data showed a 90% reduction in new heterotopic ossification lesions.
Pharma & Biotech

Can āshibio’s andecaliximab stop abnormal bone growth? An 86.2% flare-up reduction raises the stakes

āshibio reports 86.2% fewer FOP flare-ups with andecaliximab in early data, but placebo-controlled evidence remains pending.

Read More